Amikacin, Random, Serum
Use
This test is useful for monitoring the adequacy of blood concentration during amikacin therapy. Amikacin is an aminoglycoside used to treat severe blood infections by susceptible strains of gram-negative bacteria. Monitoring is crucial as peak serum concentrations and serum half-lives vary based on renal function and route of administration. Monitoring helps in preventing toxicity and ensuring efficacy by maintaining appropriate drug levels in the blood.
Special Instructions
Specimen for a peak level should be collected 30 to 60 minutes after the last dose; order PAMIK / Amikacin, Peak, Serum. Specimen for a trough level should be collected immediately before the next scheduled dose; order TAMIK / Amikacin, Trough, Serum. If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.
Limitations
Amikacin therapy requires careful monitoring, especially in patients with impaired renal function, due to the potential for accumulation and prolonged serum half-lives, which can lead to toxicity. Toxicity may present as dizziness, vertigo, hearing loss, or nephrotoxicity. Aminoglycosides are primarily excreted through glomerular filtration, thus renal impairment can significantly affect drug levels and toxicity risk.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Other)
Biomarkers
LOINC Codes
- 35669-1
- 35669-1
Result Turnaround Time
0-1 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.25 mL
Container
Plastic vial
Collection Instructions
Serum gel tubes should be centrifuged within 2 hours of collection. Red-top tubes should be centrifuged, and the serum aliquoted into a plastic vial within 2 hours of collection.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 14 days |
| Frozen | 28 days |